mirtazapine has been researched along with Cruveilhier-Baumgarten Syndrome in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Cruveilhier-Baumgarten Syndrome: Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Tanbouly, DM | 1 |
| Wadie, W | 1 |
| Sayed, RH | 1 |
1 other study available for mirtazapine and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Modulation of TGF-β/Smad and ERK signaling pathways mediates the anti-fibrotic effect of mirtazapine in mice.
Topics: Animals; Antioxidants; Collagen; Glutathione; Hepatic Stellate Cells; Hypertension, Portal; Lipid Pe | 2017 |